8-K: The Oncology Institute Reports 21.8% Revenue Increase in Q3 2024, Despite Gross Profit Decline

The Oncology Institute (TOI) announced a 21.8% increase in revenue for the third quarter of 2024, driven by strong dispensary performance, while also reporting a decrease in gross profit and an adjusted EBITDA loss.

Summary

• The Oncology Institute (TOI) reported its financial results for the third quarter of 2024, showing a significant revenue increase of 21.8% year-over-year, reaching $99.9 million.
• This revenue growth was primarily fueled by a 79.9% surge in dispensary revenue, attributed to increased prescription fills at their California pharmacy.
• However, gross profit decreased by 10.1% to $14.4 million, with a gross margin of 14.4%, down from 19.5% in the prior year quarter, due to cost management fluctuations and DIR fee run out of oral and IV drugs.
• The company's net loss was $16.1 million, an improvement from the $17.4 million loss in the same quarter last year.
• Adjusted EBITDA was a loss of $8.2 million, compared to a loss of $5.3 million in the prior year quarter, primarily due to the decrease in gross profit.
• SG&A expenses decreased by 6% year-over-year, reflecting cost-cutting measures and vendor negotiations.
• For the nine months ended September 30, 2024, consolidated revenue was $293.1 million, a 22.9% increase year-over-year, while the net loss was $51.5 million, an improvement from the $64.3 million loss in the same period last year.
• The company has completed its review of strategic alternatives and will continue with its current strategic plan.
• TOI has $47.4 million in cash and cash equivalents as of September 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there is strong revenue growth, the decrease in gross profit and increased EBITDA loss are concerning. The company is making progress in some areas, but there are clear financial challenges.

Positives

• The company experienced a significant 21.8% increase in consolidated revenue in Q3 2024.
• Dispensary revenue grew by 79.9% year-over-year, indicating strong performance in this segment.
• SG&A expenses were reduced by 6% compared to the same quarter last year, showing improved cost management.
• The net loss decreased by $1.3 million compared to the same quarter last year.
• The company secured 3 new capitation contracts and expanded its reach in Florida with a second contract.
• TOI achieved certification for radiopharmaceutical therapy in California, expanding its service offerings.
• The company opened its first two clinics in Oregon, expanding its geographic footprint.

Negatives

• Gross profit decreased by 10.1% compared to the prior year quarter, impacting overall profitability.
• Gross margin decreased from 19.5% to 14.4% year-over-year.
• Adjusted EBITDA was a loss of $8.2 million, which is worse than the $5.3 million loss in the prior year quarter.
• Patient services revenue decreased by 7.2% compared to the same quarter last year.

Risks

• The company is experiencing ongoing cost management fluctuations that are impacting gross profit.
• The decrease in gross profit is negatively impacting adjusted EBITDA.
• The company is navigating a dynamic environment, which could pose challenges to future performance.
• The company's financial results are subject to a number of risks and uncertainties, including those discussed in their SEC filings.

Future Outlook

The company will continue with its current strategic plan, focusing on growth, operational efficiency, and delivering value to customers and shareholders. Management will discuss future financial and operational performance on a conference call.

Management Comments

• Daniel Virnich, CEO of TOI, stated that they are pleased to report strong results for the third quarter of 2024, reflecting their focus on growth and operational efficiency.
• He also noted that they continued to break monthly fill records for their oral drug revenue and reduced SG&A expenses.

Industry Context

The Oncology Institute's focus on value-based care and expansion into new markets aligns with the broader industry trend of shifting towards more efficient and patient-centric healthcare models. The company's growth in dispensary revenue and capitation contracts reflects a move towards integrated care delivery.

Comparison to Industry Standards

• While TOI's revenue growth of 21.8% is strong, the decrease in gross profit and adjusted EBITDA loss are concerning when compared to other established healthcare providers.
• Companies like US Oncology and McKesson, which also operate in the oncology space, typically aim for higher gross margins and positive EBITDA.
• TOI's expansion into radiopharmaceutical therapy is a positive differentiator, as this is a growing area of oncology care, but it is still early to compare to established players in this niche.
• The company's focus on capitation contracts is a positive move towards value-based care, but the financial impact of these contracts will need to be monitored over time.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decrease in gross profit and increased adjusted EBITDA loss.
• Employees may be impacted by cost-cutting measures and vendor negotiations.
• Customers may benefit from the expansion of services and new clinic locations.
• Suppliers may be affected by the company's cost management efforts.

Next Steps

• The company will host a conference call to discuss the third quarter results and management's outlook.
• TOI will continue to execute its current strategic plan.

Key Dates

Keywords

Oncology, Financial Results, Revenue, Dispensary, Capitation Contracts, EBITDA, Gross Profit, Healthcare, Radiopharmaceutical Therapy, Medicare Advantage